D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

D. E. Shaw & Co. Inc. lessened its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 43.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 188,583 shares of the biotechnology company’s stock after selling 146,198 shares during the period. D. E. Shaw & Co. Inc. owned 0.32% of Aldeyra Therapeutics worth $941,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 2,822 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at about $69,000. AlphaCentric Advisors LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at about $234,000. Boston Financial Mangement LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at about $141,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at about $3,628,000. Institutional investors own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ALDX shares. Wall Street Zen raised shares of Aldeyra Therapeutics to a “sell” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday, May 19th. Finally, BTIG Research lowered their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, April 7th.

Aldeyra Therapeutics Stock Down 1.3%

Shares of ALDX stock opened at $2.22 on Friday. Aldeyra Therapeutics, Inc has a 12 month low of $1.14 and a 12 month high of $7.20. The stock has a market cap of $132.97 million, a P/E ratio of -2.29 and a beta of 0.92. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a 50 day simple moving average of $3.12 and a two-hundred day simple moving average of $4.63.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08. On average, research analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Aldeyra Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. The trade was a 36.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 9.60% of the stock is owned by company insiders.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.